Takeda (NYSE: TAK) executive discloses 193,148 ADS and 85,802 RSUs

Rhea-AI Filing Summary

Takeda Pharmaceutical executive Teresa Marie Bitetti, President of the Oncology Business Unit, reports beneficial ownership of 193,148 American Depositary Shares. This total includes 85,802 restricted stock units, each convertible into one ADS.

The RSUs are scheduled to vest in three tranches: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028, providing a clearly defined equity vesting timeline.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bitetti Teresa Marie

(Last) (First) (Middle)

40 LANDSDOWNE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, OBU

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	193,148(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 85,802 restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (40,056 shares), July 1, 2027 (30,564 shares) and July 1, 2028 (15,182 shares).

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Teresa Bitetti	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position does Teresa Marie Bitetti hold at Takeda (TAK)?

Teresa Marie Bitetti is identified as an officer of Takeda, serving as President of the Oncology Business Unit (OBU). This role ties her equity holdings and restricted stock units directly to the company’s oncology-focused operations and long-term performance incentives.

How many Takeda (TAK) American Depositary Shares does Teresa Bitetti report owning?

Teresa Bitetti reports beneficial ownership of 193,148 American Depositary Shares of Takeda Pharmaceutical. This figure represents her total direct holdings, including both currently held shares and restricted stock units that are scheduled to vest over future years.

How many restricted stock units are included in Teresa Bitetti’s Takeda (TAK) holdings?

Her reported position includes 85,802 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Takeda American Depositary Share, aligning a substantial portion of her compensation with the company’s future share performance over a defined vesting schedule.

What is the vesting schedule for Teresa Bitetti’s Takeda (TAK) RSUs?

The RSUs vest in three installments: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028. This staggered schedule supports ongoing retention and long-term performance alignment.

Do Teresa Bitetti’s Takeda (TAK) restricted stock units convert into actual shares?

Yes. Each restricted stock unit represents a contingent right to receive one American Depositary Share of Takeda upon vesting. As the RSUs vest on their scheduled dates, they can increase her directly held ADS position over time.